April 4, 2026
Decision Guide
CAR-T Therapy for Multiple Myeloma: Who Is Eligible and What to Expect
A guide for international patients on CAR-T therapy eligibility for multiple myeloma — covering disease status, prior treatment requirements, the step-by-step process, preparation, and what to expect when coordinating care in China.
ChinaMed Waypoint
Read Full Article
Key Highlights
- Five eligibility factors: disease status, prior therapies, overall health, disease burden, and MDT-based review
- Six-step treatment process from evaluation through leukapheresis, cell engineering, conditioning, infusion, and monitoring
- Why eligibility assessment for myeloma CAR-T requires pathology, imaging, and multidisciplinary discussion
- What international patients should prepare medically and logistically before and during treatment
- The role of caregivers and why their own wellbeing also needs planning
Important Facts
- CAR-T for myeloma is typically considered after relapse or when prior therapies are no longer working
- Eligibility requires a thorough clinical evaluation — not a simple checklist
- International patients often begin with a remote MDT consultation before traveling to confirm appropriateness
- Clarity before commitment: understanding the process reduces both uncertainty and avoidable urgency